A Phase II Study of Bevacizumab in Combination With Metronomic Temozolomide for Recurrent Malignant Glioma
This is a phase II trial of the combination of Avastin and metronomic temozolomide in
recurrent WHO grade IV malignant glioma patients. Patients will receive up to 12 cycles of
Avastin and temozolomide and cycles are continuous 28 days. Patients will receive daily
temozolomide at a dose of 50mg/m2 and will receive Avastin every other week at a dose of
10mg/kg. Patients will be required to have a baseline MRI within 2 weeks of starting
treatment and a repeat MRI every 8 weeks. A total of 32 patients will be enrolled at Duke.
Patients with recurrent malignant gliomas have a very poor prognosis, so new therapies are
needed. Given the activity of metronomic temozolomide and the safety and activity of
Avastin against malignant glioma, it is reasonable to study the combination in recurrent
malignant glioma patients.
Interventional
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
6-Month Progression-free Survival
Percentage of participants surviving six months from the start of study treatment without progression of disease. PFS was defined as the time from the date of study treatment initiation to the date of the first documented progression according to the Macdonald criteria, or to death due to any cause. [Optional: Macdonald criteria are standard criteria in neuro-oncology. Tumor assessment was made according to the adapted MacDonald criteria based on the combined evaluation of: 1) assessment of the MRI scan for measurable, evaluable, and new lesions (made by the independent external expert too), 2) overall assessment of neurological performance (made by the investigator), 3) concomitant steroid use (as reported by the investigator).]
6 months
No
Annick Desjardins, MD
Principal Investigator
Duke University Health System
United States: Institutional Review Board
Pro00000404
NCT00501891
July 2007
November 2009
Name | Location |
---|---|
Duke University Medical Center (Brain Tumor Center) | Durham, North Carolina 27710 |